Journey Strategic Wealth’s Larimar Therapeutics LRMR Stock Holding History

Journey Strategic Wealth’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$161K	Buy	35,883 +47	+0.1%	+$188	﹤0.01%	790
2025 Q4	$137K	Sell	35,836 -20	-0.1%	-$78	﹤0.01%	742
2025 Q3	$116K	Buy	35,856 +161	+0.5%	+$604	﹤0.01%	694
2025 Q2	$103K	Buy	35,695 +379	+1%	+$877	﹤0.01%	649
2025 Q1	$75.9K	Buy	35,316 +46	+0.1%	+$145	﹤0.01%	499
2024 Q4	$136K	Sell	35,270 -7	-0%	-$46	0.01%	486
2024 Q3	$231K	Hold	35,277	–	–	0.01%	424
2024 Q2	$256K	Buy	35,277 +17	+0%	+$130	0.01%	296
2024 Q1	$268K	Hold	35,260	–	–	0.01%	212
2023 Q4	$160K	Hold	35,260	–	–	0.01%	213
2023 Q3	$139K	Hold	35,260	–	–	0.01%	184
2023 Q2	$110K	Buy	+35,260	New	+$144K	0.01%	187

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Journey Strategic Wealth's LRMR Position: Q1 2026 in Review

Journey Strategic Wealth increased its Larimar Therapeutics (LRMR) stake by 0.13% in Q1 2026, buying an estimated $188 and bringing the position to 35,883 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #790.

Journey Strategic Wealth first reported a position in LRMR in Q2 2023 and has held it in 12 quarters since. The position peaked at $268K in Q1 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Journey Strategic Wealth held 35,883 shares of Larimar Therapeutics worth $161K as of Q1 2026.
Journey Strategic Wealth bought 47 Larimar Therapeutics shares in Q1 2026, an estimated $188.
Larimar Therapeutics made up ﹤0.01% of Journey Strategic Wealth's portfolio in Q1 2026, its #790 holding.
Journey Strategic Wealth first reported a position in Larimar Therapeutics in Q2 2023 and has held it in 12 quarters since.
Journey Strategic Wealth's Larimar Therapeutics position peaked at $268K in Q1 2024.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.